Terguride in the treatment of Parkinson disease: preliminary experience. 1990

P Giovannini, and I Piccolo, and S Genitrini, and F Girotti, and D Testa, and G Scigliano, and I Suchy
Centro per lo Studio del Morbo di Parkinson e le Malattie Extrapiramidali, Istituto Nazionale, Neurologico C. Besta, Milano.

Terguride, a partial DA-agonist with both dopaminergic and antidopaminergic properties, was tested in 11 PD patients in the "decompensated" phase of the disease, characterized by the presence of dyskinesias and motor fluctuations. Combined treatment of these patients with 1 mg/day of terguride and stabilized doses of levodopa reduced the severity and frequency of dyskinesias and motor fluctuations along with a slight but significant improvement of parkinsonian clinical picture. The "modulatory" effect of terguride on DA receptors, in this experimental conditions, is discussed.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008090 Lisuride An ergot derivative that acts as an agonist at dopamine D2 receptors (DOPAMINE AGONISTS). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (SEROTONIN RECEPTOR AGONISTS). Lysuride Hydrogen Maleate,Methylergol Carbamide,Arolac,Cuvalit,Dopergin,Dopergine,Lisuride Hydrochloride,Lisuride Maleate,Lisuride Maleate (1:1),Lisuride Maleate, (8beta)-Isomer,Lisuride Mesylate,Lisuride Phosphate (1:1),Lisuride, (8alpha)-(+-)-Isomer,Lysenyl,Lysurid,Revanil,Carbamide, Methylergol,Hydrochloride, Lisuride,Hydrogen Maleate, Lysuride,Maleate, Lisuride,Mesylate, Lisuride
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

P Giovannini, and I Piccolo, and S Genitrini, and F Girotti, and D Testa, and G Scigliano, and I Suchy
January 2004, Clinical neuropharmacology,
P Giovannini, and I Piccolo, and S Genitrini, and F Girotti, and D Testa, and G Scigliano, and I Suchy
January 1987, Advances in neurology,
P Giovannini, and I Piccolo, and S Genitrini, and F Girotti, and D Testa, and G Scigliano, and I Suchy
January 1990, Acta Universitatis Palackianae Olomucensis Facultatis Medicae,
P Giovannini, and I Piccolo, and S Genitrini, and F Girotti, and D Testa, and G Scigliano, and I Suchy
January 1995, Functional neurology,
P Giovannini, and I Piccolo, and S Genitrini, and F Girotti, and D Testa, and G Scigliano, and I Suchy
August 2010, Nature reviews. Neurology,
P Giovannini, and I Piccolo, and S Genitrini, and F Girotti, and D Testa, and G Scigliano, and I Suchy
January 2003, Neurologia i neurochirurgia polska,
P Giovannini, and I Piccolo, and S Genitrini, and F Girotti, and D Testa, and G Scigliano, and I Suchy
September 2003, Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology,
P Giovannini, and I Piccolo, and S Genitrini, and F Girotti, and D Testa, and G Scigliano, and I Suchy
March 2017, Parkinsonism & related disorders,
P Giovannini, and I Piccolo, and S Genitrini, and F Girotti, and D Testa, and G Scigliano, and I Suchy
January 1986, Casopis lekaru ceskych,
P Giovannini, and I Piccolo, and S Genitrini, and F Girotti, and D Testa, and G Scigliano, and I Suchy
December 1997, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica,
Copied contents to your clipboard!